Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beta-Lactam Plus Azithromycin or Doxycycline vs Fluoroquinolones in Adult Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Network Meta-analysis.

Open forum infectious diseases·2026
Same author

Clinical Utility of Copy Number Abnormality Analysis in the Evaluation of Melanocytic Lesions for Diagnosis and Prognosis: An Evidence-Based Review from the Cancer Genomics Consortium Working Group for Melanocytic Lesions.

Genes·2026
Same author

The burden of shared decision-making: A scoping review of burden assessments in SDM research.

Patient education and counseling·2026
Same author

Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel.

Journal of the neurological sciences·2026
Same author

Cutaneous T-cell lymphoma in pregnancy and postpartum period: A systematic review.

Journal of the American Academy of Dermatology·2025
Same author

Implantable peripheral nerve stimulation for chronic pain: a systematic review and meta-analysis of analgesic outcomes up to 24 months.

Regional anesthesia and pain medicine·2025

Related Experiment Video

Updated: Jun 21, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer.

Raed Benkhadra1, Tarek Nayfeh2, Sai Krishna Patibandla3

  • 1Allegheny General Hospital, Pittsburgh, PA, USA.

Bladder Cancer (Amsterdam, Netherlands)
|July 12, 2024
PubMed
Summary

Comparing chemotherapy regimens for muscle invasive bladder cancer (MIBC), gemcitabine and cisplatin (GC) showed comparable efficacy to methotrexate, vinblastine, adriamycin, and cisplatin (MVAC). Accelerated dose-dense MVAC demonstrated better downstaging and survival, but GC offered a superior safety profile.

Keywords:
Bladder cancercisplatin

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.5K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K

Related Experiment Videos

Last Updated: Jun 21, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.5K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.2K

Area of Science:

  • Oncology
  • Urologic Oncology
  • Clinical Pharmacology

Background:

  • Cisplatin-based neoadjuvant chemotherapy is the standard treatment for muscle invasive bladder cancer (MIBC).
  • Two primary regimens, gemcitabine and cisplatin (GC) and methotrexate, vinblastine, adriamycin, and cisplatin (MVAC), are commonly utilized.
  • Understanding the comparative efficacy and safety of these regimens is crucial for optimizing patient outcomes.

Purpose of the Study:

  • To conduct a meta-analysis comparing the efficacy and safety of GC versus conventional and accelerated (dose-dense) MVAC regimens in patients with MIBC.
  • To evaluate outcomes including overall survival, downstaging, pathologic complete response, recurrence, and toxicity profiles.

Main Methods:

  • A systematic literature search was performed across major databases (MEDLINE, Embase, Scopus).
  • Meta-analysis was conducted using a random-effects model to synthesize data from identified studies.
  • Key efficacy and safety endpoints were extracted and analyzed.

Main Results:

  • Overall efficacy between MVAC and GC regimens for MIBC was comparable.
  • Accelerated dose-dense MVAC showed improved downstaging and reduced all-cause mortality compared to GC.
  • GC demonstrated a better safety profile, with lower rates of febrile neutropenia, anemia, and nausea/vomiting compared to dd-MVAC, though with increased thrombocytopenia risk.

Conclusions:

  • While efficacy outcomes are generally comparable between MVAC and GC, accelerated dose-dense MVAC may offer survival benefits.
  • GC presents a more favorable safety profile regarding specific toxicities.
  • Further high-quality evidence from a Phase III randomized trial is necessary to definitively guide clinical practice for MIBC treatment.